

ASX ANNOUNCEMENT

Expiry of Unlisted Options

9th December 2020: Analytica Ltd (ASX: ALT),

The Company advises that the following unlisted options expire on 5pm 9th December 2020:

Number of unlisted options: 14,000,000

Exercise Price: \$0.0162 cents per option

The following shares and options remain outstanding

Listed issued share capital 3,519,612,332

Unlisted options

Expiry date	Exercise Price	Options on Issue	Total Number of Options on Issue
22 December 2021	\$0.013		72,500,000
5 November 2021	\$0.013	41,000,000	
8 th June 2022	\$0.01036	33,350,000	
30 November 2022	\$0.013	20,000,000	94,350,000
Total Unlisted options			166,850,000

Authorised for release by the Board.

Bryan Dulhunty
Company Secretary

For more information, please contact: investorrelations@analyticamedical.com
 For more information about the PeriCoach System, visit: www.PeriCoach.com
 For more information about Analytica, visit www.AnalyticaMedical.com





About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance for urinary incontinence in Australia and has CE mark and USFDA 510(k) clearance.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.